Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EZR in Relapsed or Refractory Follicular Lymphoma or Marginal Zone Lymphoma
NCT06563596Phase 2Recruiting
- Start
- Jan 2025
- Primary completion
- Mar 2030
- Modality
- Fragment-Derived Small Molecules, Antibody Conjugates, Reversible Covalent Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of epcoritamab, zanubrutinib in follicular lymphoma (FL), marginal zone lymphoma (MZL). Started Jan 2025; status: recruiting.
02
Drugs
epcoritamabzanubrutinib
03
Conditions
follicular lymphoma (FL)marginal zone lymphoma (MZL)
Beyond the preview
Go deeper on NCT06563596.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06563596.